James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

Allurion’s intragastric balloon has demonstrated yet more positive efficacy and safety results in a study on patients living ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for ...

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for ...

which is the first FDA pivotal trial for an intragastric balloon to report outcomes beyond nine months, involved 550 subjects. They were randomized to receive either two cycles of the Allurion ...

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for weight ...

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...